Floatz logo

LAC VACCINUM

Dyslipidemias

University of Torontoother_biologicalN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Dyslipidemias cohort.

Asset / SponsorPhaseRating
Lipitor
Johns Hopkins University
Phase 4A
Rosuvastatin
Korea University Anam Hospital
Phase 4A
Metformin
RenJi Hospital
Phase 4BBB
SIMVASTATIN
Eli Lilly and Company
Phase 4BBB
Lipitor
National Institute of Kidney Disease and Urology (NIKDU)
Phase 4BBB

View all 50 →

Same molecule, other indications

LAC VACCINUM is also rated in:

Alzheimer diseaseDormant
C
Indicative ·
37 / 100
View asset →
obesity disorderDormant
D
Indicative ·
30 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →